CS
BBLG

Clear Street’s Bone Biologics BBLG Stock Holding History

Clear Street’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-138
Closed -$385 – 944
2025
Q3 		$385 Hold
138
– – ﹤0.01% 791
2025
Q2 		$556 Buy
+138
New +$638 ﹤0.01% 620

Other funds holding BBLG

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Clear Street's BBLG Position: Q4 2025 in Review

Clear Street sold out of Bone Biologics (BBLG) in Q4 2025, closing a stake of 138 shares — an estimated $385 sold.

Clear Street first reported a position in BBLG in Q2 2025 and held it in 2 quarters. The position peaked at $556 in Q2 2025. 7 funds tracked by Wall St. Rank hold BBLG as of Q4 2025.

  • Clear Street reported no remaining Bone Biologics position as of Q4 2025 after selling out during the quarter.
  • Clear Street sold 138 Bone Biologics shares in Q4 2025, an estimated $385.
  • Clear Street first reported a position in Bone Biologics in Q2 2025 and held it in 2 quarters.
  • Clear Street's Bone Biologics position peaked at $556 in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Bone Biologics as of Q4 2025.

Based on Clear Street's 13F filing for Q4 2025, filed 13 Feb 2026.